Inspection Record

First Royal Care Co. LLC dba Red Mountain Compounding Pharmacy — FDA 483 Findings

US FDAInspected 2019-06-14Published 2019-09-16 12 findingsDocumentation and recordsStability and storageAseptic processing and sterility assuranceEquipment and facilityLaboratory and QC controlsDeviation, CAPA, and investigationTraining and personnel

Inspectors Bryan L McguckinThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Documentation and records

Batch production and control records for each batch of drug product produced do not include an accurate reproduction of the appropriate master production or control record which was checked for accuracy, dated and signed.

2Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

3Aseptic processing and sterility assurance

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

5Equipment and facility

Written procedmes for cleaning and maintenance fail to include assignment of responsibility, description in sufficient detail of methods, equipment and materials used, description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assu...

6Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

7Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

8Deviation, CAPA, and investigation

Written records are not made of investigations into unexplained discrepancies.

9Training and personnel

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

10Laboratory and QC controls

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

11Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

12Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

About this record

Extracted automatically from the document US FDA published on 2019-09-16. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

First Royal Care Co. LLC dba Red Mountain Compounding Pharmacy company profile — full history US FDA documents, 2019 Go to Findings search